Atossa Genetics Reports First Quarter 2013 Results and Operating Highlights
(firmenpresse) - SEATTLE, WA -- (Marketwired) -- 05/15/13 -- Atossa Genetics, Inc. (NASDAQ: ATOS), the Breast Health Company™, today announced its first quarter 2013 financial results and corporate developments.
"The national rollout of our is proceeding well and we are pleased with the response we are getting from the physician community and from patients," stated Dr. Steven Quay, chairman, CEO and president. "We were particularly pleased to have completed an , which provides primary care physician practices, physician groups and healthcare facilities of all sizes with cutting edge medical devices focused primarily on preventive care through early detection. Millennium has initially submitted an order for 10,000 ForeCYTE Breast Health collection kits for distribution to its network of physicians' offices in the New York Metro area and Northern New Jersey. We anticipate signing up additional distributors this year and continuing to build our internal sales and marketing team."
Continued the , which the Company launched in January 2013.
Completed a with Aspire Capital Fund, LLC. Upon signing the agreement, Aspire purchased $1.0 million of Atossa's stock at $12.00 per share. Aspire has committed to purchase up to $29 million of Atossa's common stock over the next three years at prices based on prevailing market prices over a period preceding each sale.
Signed a distribution agreement with Millennium HealthCare, Inc. Millennium placed an initial purchase order for 10,000 , which it intends to distribute to its physician practices in the New York Metro Area and Northern New Jersey.
Two leading breast centers in Texas, Aurora Breast Center in San Antonio and The Breast Center at Wellness Lubbock in Lubbock, will begin offering the ForeCYTE test to their patients. Three breast centers in Texas are now offering the ForeCYTE test.
Launched a Nationwide Awareness Program including a new to educate women and health care providers on the prevention of breast cancer by early testing for pre-cancerous breast conditions using the ForeCYTE Breast Health Test.
Continued development of the test, which is designed to identify the particular duct that is undergoing pre-cancerous or cancerous changes, and the test, which uses genomic analysis to provide important insights to inform and improve the effectiveness of breast cancer treatment for women with early-stage breast cancer. Atossa intends to launch both of these tests in 2013.
Atossa exhibited the ForeCYTE test at the 61st Annual Clinical Meeting of the American Congress of Obstetrics and Gynecology in New Orleans, the largest gathering of OB/GYNs in the U.S.
Revenues for the three months ended March 31, 2013, were $182,670, which included $13,440 of product revenue from the sale of MASCT Systems and $169,230 of diagnostic testing service revenue from the ForeCYTE breast health tests. This compares with total revenues of $54,713 for the first quarter ended March 31, 2012. The year-over-year increase in total revenue was driven by the national rollout of the ForeCYTE test in January 2013.
Gross profit for the three months ended March 31, 2013, was $116,206. This compares to gross profit of $27,709 for the quarter ended March 31, 2012.
Net loss for the quarter ended March 31, 2013, was $1.9 million, or $(0.14) per share, compared with net loss of $1.1 million, or $(0.09) per share, for the first quarter ended March 31, 2012. The increase in net loss was primarily attributable to an increase in general and administrative expense of $963,420, including increased expenses related to the national launch of the ForeCYTE test.
Total operating expenses were $2.1 million for the three months ended March 31, 2013, consisting of G&A expenses of $1.6 million, selling expenses of $272,575 and research and development expenses of $220,192. This compares to total operating expenses of $1.1 million for the three months ended March 31, 2012, consisting of G&A expenses of $601,452, selling expenses of $70,435 and research and development expenses of $417,990. The increase in G&A expenses of $963,420, from the first quarter of 2012 to the first quarter of 2013, is attributed to the launch of the Company's MASCT System, ForeCYTE test and ArgusCYTE test and the related growth in expenses to hire additional staff and expand the Company's operations. Atossa expects that its G&A expenses will continue to increase as it adds additional employees and incurs additional costs as a publicly traded company. Additionally, G&A costs are expected to rise as the Company increases headcount to coordinate the production and manufacture of the MASCT System, and the expected increase in service revenue. Selling expenses increased $202,140 from the first quarter of 2012 to the first quarter of 2013 as a result of hiring additional sales and marketing personnel and incurring additional marketing expenses directly and to the Company's distributor for the national launch of the ForeCYTE test. Research and development expenses decreased by $197,798 from the first quarter of 2012 to the first quarter of 2013 as a result of completion of the development of the ForeCYTE test and ArgusCYTE test in 2012 and as a result of Atossa's focus in 2013 on the national launch of ForeCYTE.
At March 31, 2013, Atossa had cash and cash equivalents of $1.4 million.
Atossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company™, is based in Seattle, WA, and is focused on preventing breast cancer through the commercialization of patented, FDA-designated Class II diagnostic medical devices and patented, laboratory developed tests (LDT) that can detect precursors to breast cancer up to eight years before mammography, and through research and development that will permit it to commercialize treatments for pre-cancerous lesions.
The , a wholly owned subsidiary of Atossa Genetics, Inc., is a CLIA-certified high-complexity molecular diagnostic laboratory located in Seattle, WA, that provides the patented ForeCYTE Breast Health Test, a risk assessment test for women 18 to 73 years of age akin to the Pap Smear, and the , a blood test for recurrence in breast cancer survivors that provides a "liquid biopsy" for circulating cancer cells and a tailored treatment plan for patients and their caregivers.
Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, regulatory clearances, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, the efficacy of Atossa's products and services, the market demand for and acceptance of Atossa's products and services, performance of distributors and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its registration statement on Form S-1 filed April 5, 2013, and periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Atossa Genetics, Inc.
Kyle Guse
Chief Financial Officer and General Counsel
800-351-3902
Matthew D. Haines (Investors)
Managing Director
MBS Value Partners
212-710-9686
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 15.05.2013 - 06:30 Uhr
Sprache: Deutsch
News-ID 1227557
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SEATTLE, WA
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 272 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Atossa Genetics Reports First Quarter 2013 Results and Operating Highlights
"
steht unter der journalistisch-redaktionellen Verantwortung von
Atossa Genetics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
